The Iowa-Mayo SPORE Biospecimens Shared Resource provides a coordinated, centralized, and dedicated core for the procurement, processing and annotafion of biospecimens from lymphoma patients and pafients with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL). The goal of the Biospecimens Core is to procure a variety of biologic specimens on all patients involved in UI/MC SPORE protocols and all newly diagnosed lymphoma pafients seen at the University of lowa and the Mayo Clinic Rochester, who are enrolled into the Molecular Epidemiology Resource (MER).
The specific aims ef the Biospecimens Core are: 1) To provide accurate classification of all lymphomas from patients enrolled onto SPORE protocols and the MER;2) To collect, process, bank and distribute biologic specimens from lowa and Mayo lymphoma patients for translafional research;3) To track all biospecimens and ensure linkage to clinical, outcome and related data;and 4) Te serve as a resource of expertise, collaborative support and service for projects. All specimens are collected and processed under tight quality control, and distributed to SPORE researchers or banked for future SPORE research projects. These activities are tracked using a sophisticated database that merges the activities at lowa and Mayo, and allows integration with clinical and other data collected in research projects. The Core provides specialized expertise in working with lymphoma biospecimens and is closely aligned with institutional research cores and shared resources, but does not duplicate them. During the last funding period, the Core collected biospecimens from 7 SPORE clinical trials (>1000 samples from 193 pafients). The Core also reviewed and classified 2,461 pafients for enrollment into the MER, and collected germline DNA on >2S00 and serum on >2100 ofthe MER patients. The Core additionally banked frozen cells on -400 patients. The Cere has supported all of the full projects and multiple Developmental and Career Development projects. There has been extensive utilization of biospecimens, including use of paraffin and frozen tissue;frozen cells;germline DNA;and serum and plasma, all leading to extensive publications involving the Core. The Biospecimens Core has also partnered on other projects that have obtained extramural funding to support epidemiologic studies, family studies, genome-wide association studies, inter-SPORE studies, and other ROI and POl projects. In the next grant cycle, we will continue to accrue new patient samples to the bank and work with investigators to utilize this increasingly valuable resource to support translational research projects in lymphoma.

Public Health Relevance

Well-characterized, pathologically and clinically annotated tumor tissues from patients with malignant lymphoma are a critical and valuable resource for translating the basic molecular and biological understanding of lymphomas into improved treatments for patients. The UI/MC Lymphoma SPORE meets these needs by linking the biospecimens resource with ether ceres and the MER.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097274-11
Application #
8395832
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2002-09-11
Project End
2017-06-30
Budget Start
2012-09-12
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$296,219
Indirect Cost
$26,202
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Johnston, Patrick B; LaPlant, Betsy; McPhail, Ellen et al. (2016) Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol 3:e309-16
Wongrakpanich, Amaraporn; Mudunkotuwa, Imali A; Geary, Sean M et al. (2016) Size-dependent cytotoxicity of copper oxide nanoparticles in lung epithelial cells. Environ Sci Nano 3:365-374
Ahmed, Kawther K; Geary, Sean M; Salem, Aliasger K (2016) Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine. J Pharm Sci 105:1173-9
Boddicker, Rebecca L; Razidlo, Gina L; Dasari, Surendra et al. (2016) Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood 128:1234-45
King, Rebecca L; Dao, Linda N; McPhail, Ellen D et al. (2016) Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. Am J Surg Pathol 40:36-43
Maurer, Matthew J; Jais, Jean-Philippe; Ghesquières, Hervé et al. (2016) Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol 91:179-84
Parry, Helen Marie; Damery, Sarah; Hudson, Christopher et al. (2016) Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. Am J Hematol 91:776-81
Machiela, Mitchell J; Lan, Qing; Slager, Susan L et al. (2016) Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Hum Mol Genet 25:1663-76
Mambetsariev, Nurbek; Lin, Wai W; Stunz, Laura L et al. (2016) Nuclear TRAF3 is a negative regulator of CREB in B cells. Proc Natl Acad Sci U S A 113:1032-7
Kenderian, Saad Sirop; Habermann, Thomas M; Macon, William R et al. (2016) Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood 127:1960-6

Showing the most recent 10 out of 313 publications